Form 4: LifeCore Biomedical CEO Paul Josephs Acquires 150,000 Shares Following Performance Milestone Achievement

LifeCore Biomedical, Inc. CEO and Director Paul Josephs acquired 150,000 shares of common stock through the vesting of performance-based restricted stock units, indicating the company achieved a stock price milestone.

Summary

• Paul Josephs, Chief Executive Officer and Director of LIFECORE BIOMEDICAL, INC. (LFCR), acquired 150,000 shares of common stock on July 8, 2025, through the vesting of performance-based restricted stock units.
• The vesting of these units was triggered by the Issuer's achievement of a specific stock price milestone.
• Following this acquisition, Josephs' direct beneficial ownership of common stock increased to 688,185 shares.
• Concurrently, 54,857 shares were disposed of at a price of $8.19 per share to satisfy applicable tax withholding obligations related to the vesting and settlement of the performance stock unit award.
• After the tax-related disposition, Josephs' direct beneficial ownership of common stock stands at 633,328 shares.
• Josephs also holds 1,350,000 performance-based restricted stock units, which represent a contingent right to receive one share of common stock upon the Issuer's common stock achieving certain stock prices, with an expiration date of May 20, 2029.

Sentiment

Score: 7

Explanation: The vesting of performance-based restricted stock units is a positive event, indicating the company met specific stock price milestones. While shares were withheld for taxes, this is a standard procedure for such awards.

Positives

• The vesting of 150,000 performance-based restricted stock units indicates that LIFECORE BIOMEDICAL, INC. successfully achieved a predefined stock price milestone, reflecting positive company performance.
• The acquisition of a significant number of shares by the CEO demonstrates continued alignment of management's interests with those of shareholders.

Negatives

• 54,857 shares were withheld by the issuer to cover tax withholding obligations, reducing the net shares received by the CEO.

Future Outlook

This document does not contain forward-looking statements or guidance beyond the expiration date of the derivative securities.

Industry Context

This Form 4 filing details an executive's stock transaction, which is a routine disclosure for publicly traded companies. It does not provide broader industry context or trends.

Related Party Transactions

• The transaction involves the Chief Executive Officer and Director of LIFECORE BIOMEDICAL, INC. acquiring shares from the company, which constitutes a related party transaction.

Stakeholder Impact

• Shareholders may view the vesting of performance-based units as a positive sign, as it indicates the company has met certain performance targets, potentially leading to increased confidence in management and the company's stock.

Key Dates

Keywords

LIFECORE BIOMEDICAL, LFCR, Paul Josephs, CEO, Director, SEC Form 4, Insider Trading, Stock Vesting, Restricted Stock Units, Executive Compensation, Stock Price Milestone